The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 65-70

  Miceli, J J ^a   Anziano, R J ^a   Robarge, L ^a   Hansen, R A ^a   Laurent, A ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Pfizer Central Research ^*  (United States)

Author keywords

Carbamazepine; Interaction; Pharmacokinetics; Ziprasidone

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; ZIPRASIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034015675     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00157.x     Document Type: Article

References (25)

1. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform responsible for the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl. 1): 35S-42S.
2. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49(Suppl. 1): 57S-60S.
3. Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 2000; 49(Suppl. 1): 49S-56S.
4. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effect of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 71S-76S.
5. Keefe RS, Mohs RC, Losonczy MF. Characteristics of a very poor outcome in schizophrenia. Am J Psychiatry 1987; 144: 889-895.
6. Prasad AJ. Attempted suicide in hospitalised schizophrenics. Acta Psychiatr Scand 1986; 74: 41-42.
7. Blak DW, Winokur G, Warrack G. Suicide in schizophrenia: the Iowa Record Linkage Study. J Clin Psychopharmacol 1996; 16: 158-169.
8. Azorin JM. Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand 1995; 388: 20-23.
9. Albani F, Riva R, Baruzzi A, et al. Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 1995; 28: 235-244.
10. Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Aust NZ J Psychiatry 1996; 30: 20-37.
11. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995; 21: 607-619.
12. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1994; 36(Suppl 5): S8-S13.
13. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27: 397-417.
14. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996; 31: 198-214.
15. Ketter TA, Flockhart DA, Post M, et al. The emerging role of cytochrome P450 3A4 in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387-398.
16. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57(Suppl 11): 12-25.
17. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol 1990; 10: 54-57.
18. Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
19. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase excavation and narrow-bore high-performance liquid chromatography. J Chromatogr 1995; 668: 133-139.
20. Prakash C, Kamel A, Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 1997; 25: 863-872.
21. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, ed. Caddo, OK. Professional Communications. 1996.
22. Meyer MC, Baldessarini RJ, Goff DC, et al. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Safety 1996; 15: 333-346.
23. Iwahashi K, Miyatake R, Suwaki H, et al. The drug-drug effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995; 18: 233-266.
24. Tiihonen J, Vartiainen H, Hakola P, et al. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28: 26-28.
25. Misra LK, Erpanbach JE, Hamlyn H, et al. Quetiapine: a new atypical antipsychotic. SDJ Med 1998; 51: 189-193.